# Miroculus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/miroculus

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.miroculus.com
- Total disclosed funding: $23M
- Latest round: Series B (Feb 11, 2021)
- Investors on record: 3

## About

Based in California, US, and founded in 2014, mirOculus Inc. deals with the research and development of biotech tools for personal lab automation. Alejandro Tocigl (CEO), Fay Christodoulou (Chief Scientific Officer), and Jorge Soto are the co-founders of the company. In February 2021, the company closed a Series B financing which made the total capital raised in the Series to USD 45 million.

The company has its Miro Technology platform which is used for biotechnology research and development from NGS sample preparation to small molecule chemistry to synthetic biology. This technology enables scientists and researchers and clinicians everywhere to automate complex protocols and accelerate their research progress. The company’s product called Miro Canvas uses Miro technology, Miro cartridges, and Miro reagent kits. 

The company is expanding its production and enrolment for early access and participation in its Beta program for Miro canvas. The company also plans to work with more customers, add new workflows, and expand access to personal lab automation.

## Funding rounds

- Series B, Feb 11, 2021, $20M — Cota Capital, Section 32
- Seed, Apr 8, 2015, $2.8M — Nazca

## Investors

- Nazca (https://capitalatlas.ai/funds/nazca) — Seed
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B